Browse everything: Tickers A–Z · Issuers · Comparisons · Tags
ATRA Stock — Atara Biotherapeutics, Inc.
Atara Biotherapeutics, Inc. (ATRA)
Updated October 16, 2026.
ATRA is a Stock. Total return is -96.6% over the past 12 years, 496.6 points behind SPY at 400.0%.
Atara Biotherapeutics is a clinical-stage biotherapeutics company developing cell therapies for cancer and autoimmune diseases, with its most advanced program being Tab-cel, a T-cell immunotherapy in Phase 3 trials for Epstein-Barr virus-driven conditions, alongside earlier-stage programs including an allogeneic CAR T therapy targeting B-cell malignancies. The company does not currently distribute to shareholders. Atara appeals primarily to investors with high risk tolerance seeking exposure to emerging immunotherapy platforms, as it remains unprofitable and dependent on clinical trial progress and future financing.
ATRA performance versus SPY
Price and return data through 2026-10-16.
Total return is -96.6% over the past 12 years, 496.6 points behind SPY at 400.0%. Over the past year its total return — price change plus distributions reinvested — is -39.8%. Its deepest 1-year drawdown was 76.9%.
| Window | Total return | CAGR |
|---|---|---|
| 1M | -9.2% | — |
| 3M | 5.3% | — |
| 6M | 75.2% | — |
| YTD | -49.2% | — |
| 1Y | -39.8% | — |
| 2Y CAGR | — | -0.10% |
| 3Y CAGR | — | -38.20% |
| 5Y CAGR | — | -52.40% |
| 10Y CAGR | — | -31.40% |
| Since inception (12 years) | -96.6% | -24.50% |
ATRA key facts
- Asset type
- Stock
- Asset class
- Equity
- Inception date
- 10/16/2014
- Distribution frequency
- None
- Last close
- $9.18 (as of 2026-10-16)
- Market cap
- $92,146,178
- Average volume
- 19493.0
- Beta
- 0.219
- Payout ratio
- 0.0%
- Forward P/E
- 16.1551
- EPS
- $-1.30
How Dividend Vision calculates yield and returns
Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.
Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology
Sources and review
Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.
Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.
ATRA risks and drawbacks
Total return has trailed SPY over the available window. The deepest 1-year drawdown on record here is 76.9%.
Who may consider ATRA — and who may not
It is a weaker fit for investors who need monthly cash flow (ATRA does not currently distribute); investors whose main goal is matching SPY total return. This is educational context, not a recommendation to buy or sell.
More on ATRA
Frequently asked questions
Does ATRA pay monthly?
No. ATRA does not currently distribute.
When does ATRA pay a dividend?
ATRA does not currently distribute.
How has ATRA performed?
Total return is -96.6% over the past 12 years, 496.6 points behind SPY at 400.0%. Over the past year its total return — price change plus distributions reinvested — is -39.8%. Its deepest 1-year drawdown was 76.9%.
Tickers
Holdings as-of date unavailable.
| Ticker | Name | Weight |
|---|
See how this investment would fit into your portfolio.